Promacta and Revlimid drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Promacta (eltrombopag olamine) and Revlimid (lenalidomide). Common drug interactions include mass among females and diarrhoea among males.

The phase IV clinical study analyzes what interactions people have when they take Promacta and Revlimid. It is created by eHealthMe based on reports of 100 people who take the same drugs from the FDA, and is updated regularly.

What is Promacta?

Promacta has active ingredients of eltrombopag olamine. It is often used in idiopathic thrombocytopenic purpura (itp). eHealthMe is studying from 17,758 Promacta users. Check the latest studies of Promacta.

What is Revlimid?

Revlimid has active ingredients of lenalidomide. It is often used in multiple myeloma. eHealthMe is studying from 378,026 Revlimid users. Check the latest studies of Revlimid.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 18, 2026

100 people who take Promacta and Revlimid together, and have interactions are studied.

Promacta and Revlimid drug interactions.

What are the common drug interactions of Promacta and Revlimid, by gender? *:

female:

Mass
Neck pain
Neoplasm (tumour)
Night sweats (sweating in night)
Pneumonitis (inflammation of the walls of the alveoli in the lungs)
Acute myeloid leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts)
Arthralgia (joint pain)
Back pain
Bacterial infection
Blood pressure decreased

male:

Diarrhoea
Dizziness
White blood cell count decreased
Transient ischaemic attack (a transient episode of neurologic dysfunction caused by ischemia (loss of blood flow))
Drug ineffective
Fatigue (feeling of tiredness)
Red blood cell count decreased
Epistaxis (bleed from the nose)
Thrombosis (formation of a blood clot inside a blood vessel)
Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)

What are the common drug interactions of Promacta and Revlimid, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Death
Full blood count decreased

30-39:

Full blood count increased
Platelet count increased

40-49:

n/a

50-59:

White blood cell count decreased
Nausea (feeling of having an urge to vomit)
Vomiting
Abdominal discomfort
Constipation
Cough
Diarrhoea
Drug ineffective
Eating disorder
Fatigue (feeling of tiredness)

60+:

Platelet count decreased
White blood cell count decreased
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
Anaemia (lack of blood)
Dyspepsia (indigestion)
Pyrexia (fever)
Weight decreased
Asthenia (weakness)
Haemoglobin decreased
Thrombocytopenia (decrease of platelets in blood)

What are the existing conditions these people have? *

Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 24 people, 24.00%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 9 people, 9.00%
Thrombocytopenia (decrease of platelets in blood): 8 people, 8.00%

* Approximation only. Some reports may have incomplete information.

Do you take Promacta and Revlimid?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously